|
Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Soula A, Nutt D.
“Microdosing psychedelics: More questions than answers? An overview and suggestions for future research”.
J Psychopharmacol. 2019 Jul 15;p269881119857204.
|
|
Abstract
BACKGROUND: In the past few years, the issue of 'microdosing' psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing is.
AIMS: This critique paper is designed to address questions that need to be answered by future scientific studies and to offer guidelines for these studies.
APPROACH: Owing to its proximity for a possible approval in clinical use and short-lasting pharmacokinetics, our focus is predominantly on psilocybin. Psilocybin is allegedly, next to lysergic acid diethylamide (LSD), one of the two most frequently used psychedelics to microdose. Where relevant and available, data for other psychedelic drugs are also mentioned.
CONCLUSIONS: It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses. To that end, (pre)clinical studies including biological (e.g. heart rate, receptor turnover and occupancy) as well as cognitive (e.g. memory, attention) parameters have to be conducted and will shed light on the potential negative consequences microdosing could have.
|
